Drug Name: 

REGN1979

Drug Description: 
CD20XCD3 Antibody
Target Condition: 
Cancer (also in combination with REGN2810)
Rank: 
20
Phase: 
Phase 1

NOW APPROVED IN THE UNITED STATES

Learn more